Robert Norgard

Company: Boehringer Ingelheim

Job title: Sr. Scientist

Seminars:

Exhibiting a Combination of SOS1:KRAS Inhibitor with A MEK Inhibitor Reconfigures the Immune Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinomas & Sensitizes to Immunotherapy 11:45 am

Showcasing the efficacy of SOS1i and MEKi as monotherapy and combination in controlling KPCY tumor growth in vitro and in vivo Presenting how the combination of SOS1 and MEK inhibition rewires the immune tumor microenvironment Displaying how CD8+ T cells increase is restricted to the individual tumor site and resulted from both recruitment and intra-tumoral…Read more

day: Day Two Track B AM